Dashboard
Manage Tickers

INCY INCYTE CORP

Nasdaq incyte.com


$ 105.19 $ 3.10 (3.03 %)    

Wednesday, 05-Nov-2025 13:27:28 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 624.99 $ 6.54 (1.06 %)
DIA $ 473.62 $ 2.90 (0.62 %)
SPY $ 680.10 $ 5.05 (0.75 %)
TLT $ 89.04 $ -0.47 (-0.53 %)
GLD $ 366.51 $ -0.05 (-0.01 %)
$ 102.92
$ 102.28
$ 105.15 x 120
$ 105.25 x 1
$ 101.80 - $ 105.96
$ 53.56 - $ 103.86
3,531,241
na
20.21B
$ 0.48
$ 17.00
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 07-29-2025 06-30-2025 10-Q
3 04-29-2025 03-31-2025 10-Q
4 02-10-2025 12-31-2024 10-K
5 10-29-2024 09-30-2024 10-Q
6 07-30-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 02-13-2024 12-31-2023 10-K
9 10-31-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-02-2023 03-31-2023 10-Q
12 02-07-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-08-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-13-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 07-30-2019 06-30-2019 10-Q
27 04-30-2019 03-31-2019 10-Q
28 02-14-2019 12-31-2018 10-K
29 10-30-2018 09-30-2018 10-Q
30 07-31-2018 06-30-2018 10-Q
31 05-01-2018 03-31-2018 10-Q
32 02-15-2018 12-31-2017 10-K
33 10-31-2017 09-30-2017 10-Q
34 08-01-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-14-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

piper-sandler-maintains-overweight-on-incyte-raises-price-target-to-102
Piper Sandler Maintains Overweight on Incy...
11/04/2025 16:31:40

Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $82 ...

Core News & Articles
Prelude Therapeutics Signs Agreement For I...
11/04/2025 12:07:54

Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive opti...

kenvue-idexx-laboratories-freshpet-and-other-big-stocks-moving-higher-on-monday
Kenvue, IDEXX Laboratories, Freshpet And O...
11/03/2025 19:13:22

guggenheim-upgrades-incyte-to-buy-announces-125-price-target
Guggenheim Upgrades Incyte to Buy, Announc...
11/03/2025 17:11:11

Guggenheim analyst Michael Schmidt upgrades Incyte (NASDAQ:INCY) from Neutral to Buy and announces $125 price target.

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-84
RBC Capital Maintains Sector Perform on In...
10/29/2025 16:47:51

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $81...

truist-securities-reiterates-hold-on-incyte-raises-price-target-to-93
Truist Securities Reiterates Hold on Incyt...
10/29/2025 15:17:17

Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:INCY) with a Hold and raises the price target from ...

wells-fargo-maintains-overweight-on-incyte-raises-price-target-to-97
Wells Fargo Maintains Overweight on Incyte...
10/29/2025 14:14:50

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $89 to $97.

incyte-delivers-robust-growth-but-2028-patent-expiry-still-looms
Incyte Delivers Robust Growth, But 2028 Pa...
10/28/2025 18:44:20

Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its...

nasdaq-100-hits-26000-gold-falls-below-4000-whats-moving-markets-tuesday
Nasdaq 100 Hits 26,000, Gold Falls Below $...
10/28/2025 17:23:51

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

incyte-raises-fy25-net-product-revenue-guidance-to-423b---432b-lifts-guidance-for-jakafi-to-3050b---3075b
Incyte Raises FY25 Net Product Revenue Gui...
10/28/2025 11:03:00

incyte-q3-adj-eps-226-beats-166-estimate-sales-1366b-beat-1255b-estimate
Incyte Q3 Adj. EPS $2.26 Beats $1.66 Estim...
10/28/2025 11:01:04

Incyte (NASDAQ:INCY) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.66 by 36.39...

exploring-incytes-earnings-expectations
Exploring Incyte's Earnings Expectations
10/27/2025 17:02:38

incyte-partners-with-enable-injections-to-develop-easier-at-home-treatments-for-rare-blood-cancers
Incyte Partners With Enable Injections to ...
10/27/2025 11:35:40

Incyte (NASDAQ:INCY) and Enable Injections, Inc. ("Enable") today announced a new partnership to develop and commercial...

reported-saturday-incyte-reports-significant-patient-reported-benefit-in-true-ad4-with-improved-poem-and-dlqi-scores-and-reduced-worst-daily-itch-from-day-2
Reported Saturday, Incyte Reports Signific...
10/27/2025 06:45:52

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the ...

eli-lillys-new-ebglyss-results-back-flexible-treatment-options-for-atopic-dermatitis
Eli Lilly's New Ebglyss Results Back Flexi...
10/24/2025 16:06:29

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Ol...

Core News & Articles
Eli Lilly And Incyte's Baricitinib Deliver...
10/24/2025 10:55:12

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areat...

reported-sunday-incytes-inca33890-demonstrates-durable-responses-in-mss-colorectal-cancer-company-to-advance-program-toward-2026-registration
Reported Sunday, Incyte's INCA33890 Demons...
10/20/2025 07:06:34

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment i...

reported-sunday-incyte-highlights-early-clinical-results-for-inca33890-and-incb161734-showing-potential-in-advanced-solid-tumors
Reported Sunday, Incyte Highlights Early C...
10/13/2025 06:36:49

what-14-analyst-ratings-have-to-say-about-incyte
What 14 Analyst Ratings Have To Say About ...
10/09/2025 18:00:26

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION